Edition:
United Kingdom

Pfizer Inc (PFE.N)

PFE.N on New York Stock Exchange

35.37USD
17 Nov 2017
Change (% chg)

-- (--)
Prev Close
$35.37
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
4,868,122
52-wk High
$36.78
52-wk Low
$30.51

Chart for

About

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business... (more)

Overall

Beta: 0.99
Market Cap(Mil.): $214,682.30
Shares Outstanding(Mil.): 5,955.13
Dividend: 0.32
Yield (%): 3.55

Financials

  Industry Sector
P/E (TTM): -- 31.15 16.44
EPS (TTM): -- -- --
ROI: -- 14.99 10.62
ROE: -- 16.33 14.20

FDA expands approval for Pfizer cancer drug Sutent

The U.S. Food and Drug Administration on Thursday approved the use of Pfizer Inc's cancer drug Sutent to help prevent kidney cancer from returning following surgical removal of a kidney.

16 Nov 2017

U.S. FDA expands approval for Pfizer cancer drug Sutent

Nov 16 The U.S. Food and Drug Administration on Thursday approved the use of Pfizer Inc's cancer drug Sutent to help prevent kidney cancer from returning following surgical removal of a kidney.

16 Nov 2017

Pfizer, Novartis agree UK price cuts for new breast cancer drugs

LONDON Pfizer and Novartis have agreed price cuts for their rival breast cancer drugs Ibrance and Kisqali to ensure they can be used routinely within Britain's state-funded health service.

16 Nov 2017

Pfizer, Novartis agree UK price cuts for new breast cancer drugs

LONDON, Nov 16 Pfizer and Novartis have agreed price cuts for their rival breast cancer drugs Ibrance and Kisqali to ensure they can be used routinely within Britain's state-funded health service.

16 Nov 2017

Pfizer creates chief operating officer role for Bourla

NEW YORK Drugmaker Pfizer Inc has promoted Albert Bourla to the newly created post of chief operating officer, freeing up Chief Executive Officer Ian Read to focus more on long-term strategy and engaging with government and industry leaders.

13 Nov 2017

UPDATE 1-Pfizer creates chief operating officer role for Bourla

NEW YORK, Nov 13 Drugmaker Pfizer Inc has promoted Albert Bourla to the newly created post of chief operating officer, freeing up Chief Executive Officer Ian Read to focus more on long-term strategy and engaging with government and industry leaders.

13 Nov 2017

BRIEF-Pfizer names Albert Bourla chief operating officer

* Pfizer - ‍albert Bourla has been group president of co's innovative health business since beginning of 2016​

13 Nov 2017

Pfizer exits China joint venture for generic drugs

Pfizer Inc said on Friday it has sold its 49 percent stake to exit a joint venture it had set up with China's Zhejiang Hisun Pharmaceuticals in 2012 to develop and market generic drugs.

10 Nov 2017

Pfizer exits China joint venture for generic drugs

Nov 10 Pfizer Inc said on Friday it has sold its 49 percent stake to exit a joint venture it had set up with China's Zhejiang Hisun Pharmaceuticals in 2012 to develop and market generic drugs.

10 Nov 2017

AstraZeneca sales decline slows as it waits for medicine to work

LONDON AstraZeneca's drug sales fell again in the third quarter, hit by generic competition to former blockbusters like cholesterol pill Crestor, although the pace of decline slowed as it looks to new cancer treatments to revive its fortunes.

09 Nov 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $138.00 --
Novartis AG (NOVN.S) CHF83.00 -0.30
Merck & Co., Inc. (MRK.N) $55.20 --
Roche Holding Ltd. (ROG.S) CHF230.10 +1.10
Roche Holding Ltd. (RO.S) CHF244.30 +11.00
Abbott Laboratories (ABT.N) $55.56 --
Bayer AG (BAYGn.DE) €108.00 +0.45
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €75.58 +0.15
AstraZeneca plc (AZN.L) 4,977.50 +2.50

Earnings vs. Estimates